2018 Speakers Include

Transcription

1 Day 1 Stream 1 Protein Engineering, Design & Selection Novel approaches to protein engineering Novel protein conjugation strategies Improving protein half-life extension, potency & selectivity Advanced computational tools for engineering proteins Day 1 Stream 2 Biotherapeutics: Manufacturing, Chemistry, Analytics and Control Overcoming the challenges of characterising biotherapeutics Understanding protein aggregation Testing protein stability Formulations to increase stability Novel technologies & techniques to analyse biotherapeutics Developability of biotherapeutics Day 2 Stream 1 Antibody Engineering, Design & Development Advancing to the clinic: antibody drug conjugates Innovative design and engineering approaches New concepts for developing bispecific antibodies Advanced antibody structures and dynamics Advances in the generation and characterisation of antibodies Day 2 Stream 2 Cloning, Expression, Purification & Analytics Novel strategies to express proteins Overcoming the expression challenges of difficult to express proteins Updates in protein purification and analytics Updates in cryo-em techniques Detection of antibodies by LC/MS Cell line development and cell line engineering Benefits to Attending Hear from and meet with the key innovators in proteins & antibodies attendees include: Chief Medical Officer, Merck & Co., Inc.; Senior Vice President, Teva Pharmaceuticals, Vice President, Johnson & Johnson Discover collaborative solutions to protein engineering, designs and selection. Our highly established event will bring together key opinion leaders to discuss protein half-life extension updates, novel conjugation strategies and computational tools New to 2018! Discuss the latest innovations in biotherapeutics: manufacturing, chemistry, analytics and control. Topics to be covered include: characterising biotherapeutics, developability and manufacturing updates Learn more about antibody engineering, design & development. Discuss new concepts for characterising antibodies and innovative design approaches Unparalleled networking opportunities. The two-day congress offers dedicated networking breaks creating an interactive platform for scientific discussions and meetings. The exhibition hall and poster presentation spaces offer a relaxed and professional environment for scientific discussion Co-located with the highly anticipated 5th Annual Biosimilars & Biobetters Congress and 5 th Annual Peptides Congress 2018 Speakers Include Day 2 Stream 3 Protein & Antibody Biotherapeutics Fusion protein therapeutics New targets & new indications for protein biotherapeutics Accelerating antibody discovery & optimisation: o Bispecific antibodies o Monoclonal antibodies o Antibody drug conjugates Cutting edge technologies for antibody discovery Therapeutic antibody development Targeting immune checkpoints Immunogenicity of therapeutic antibodies: prediction and risk mitigation Including 5+ Think Tank Round Table Discussions Roy Baynes Katarina Radošević Sharon McGonigle MSD Sanofi R&D Eisai FREE WEBINARS 2018: Protein & Antibody Biotherapeutics Manufacturing & Developability Assessment 16 th January Register here. Antibody Biotherapeutics: Current Technologies And Recent Therapeutic Success 24 th January Register here. Meet Senior Decision Makers 450 senior attendees from leading pharmaceutical, biopharmaceutical, academics, CRO and solution provider companies will be attending. Meet Senior VPs, Directors, & Managers with the following job titles: Protein Structure Protein Expression Protein Engineering Discover New Solutions Formal and informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers. Services to be discussed include: Protein Purification Protein Technology Platforms Protein Structure Prediction Antibody Technology Antibody Discovery Antibody Therapies Custom Protein Production Custom Antibody Production Immunogenicity Assessment Manufacturing Science Analytical Development Discovery Therapeutics Display Technologies Process Development Computational Chemistry For booking details & registration fees please refer to the last page or visit: Biologics Development Biologics Profiling Biological Sciences Recombinant Antibody Antibody Analysis Protein Identification

2 2018 Confirmed Speakers Include: Roy Baynes, Chief Medical Officer, Senior Vice President and Head of Global Clinical Development, MSD David Mantus, Chief Development Officer, Arsanis Jens Frauenfeld, Chief Executive Officer, Salipro Biotech AB Yanay Ofran, Chief Executive Officer & Founder, Biolojic Design and Professor of Biophysics and Computational Biology, Bar-Ilan University Steffen Nock, Senior Vice President (Global Biologics Head), Teva Pharmaceuticals Syd Johnson, Vice President, Antibody Engineering, Macrogenics Annelise Vuidepot, Vice President, Head of Oncology Pipeline and Research, Immunocore Sanjaya Singh, Vice President and Head, Biotherapeutics, Johnson & Johnson Vincent Ling, Senior Director, Takeda Pharmaceuticals Hari Hariharan, Senior Director, Biotherapeutics, Celgene Angela Norton, Senior Director and Head, Protein & Antibody Engineering, Shire Pharmaceuticals Zhulun Wang, Executive Director, Research, Amgen Michelle Morrow, Director, Preclinical Translational Pharmacology, F-Star Biotechnology Sujata Sharma, Director, Protein Science, Merck & Co., Inc. Emma Harding, Director, Head of Molecular Design and Engineering, GlaxoSmithKline Ai Ching Lim, Director, Research, Amgen Andy Hooker, Director of Pharmaceutical Sciences, Ipsen Bioinnovation Ltd Kenneth Walker, Director of Research, Biologics, Amgen Claire Dobson, Associate Director, Antibody Discovery and Protein Expression, MedImmune Yung-Hsiang Kao, Associate Director and Principal Scientist, Genentech W. Blaine Stine, Associate Director, Discovery Biologics, AbbVie Patrick Garidel, Associate Director, Protein Chemistry, Boehringer Ingelheim Stefan Weigand, Global Head of Large Molecule Research, F.Hoffmann-La Roche Katarina Radošević, Global Head Biologics Research, Sanofi R&D Thorsten Lorenz, Group Head Developability Assessment 1, Novartis David Gervais, Head of Product Development, Porton Biopharma Alexey Rak, Head, BioStructure & Biophysics, Sanofi Darko Skegro, Senior Team Leader, Novartis Sharon McGonigle, Senior Principal Scientist, Eisai Ramu Sadhukhan, Principal Research Scientist, AbbVie Michael Chin, Senior Principal Scientist and Associate Research Fellow, Pfizer Tina Møller Tagmose, Principal Scientist, Novo Nordisk A/S Jane Seagal, Principal Research Scientist, AbbVie Sepideh Afshar, Principal Research Scientist, Department of Protein Engineering, Eli Lilly & Company Sally Fischer, Principal Scientist and Group Leader, Genentech Carsten Behrens, Principal Scientist, Novo Nordisk A/S Berthold Boedeker, Chief Scientist and Project Coordination, Bayer AG Ren Liu, Team Leader and Associate Principal Scientist, Merck & Co., Inc. Pallavi Tawde, Single B Cell Cloning Platform Leader, Bristol-Myers Squibb Dorina Saro, Senior Research Scientist, Johnson & Johnson Christopher Lloyds, Senior Scientist, Senior Scientist, Protein Engineering, MedImmune Kaimeng Zhou, Analytical Team Lead, Bristol-Myers Squibb Christian Bernloehr, Project Leader, Molecular Biology Department, Boehringer Ingelheim Zhi Chen, Senior Scientist, Molecular and Analytical Development, Global Manufacturing & Supply, Bristol-Myers Squibb Kerstin Otte, Professor, University of Applied Sciences Biberach Jon Sayers, Professor of Functional Genomics, University of Sheffield Alexander Golovanov, Senior Lecturer and Principal Investigator, Manchester Institute of Biotechnology and School of Chemistry, University of Manchester If you re on Twitter, make sure to follow and join the Congress conversation using #Proteins2018

3 2018 Proteins & Antibodies, Biosimilars & Biobetters and Peptides Congress Sponsors Include: Gold Sponsors: Bronze Sponsors: Congress Sponsors:

4 Day One 16 th April th Annual Proteins & Antibodies Congress Registration Oxford Global s Welcome Address Chairperson s Opening Address Co-located Event Keynote Address: Advanced Protein Technologies To Support Discovery Reagents For Early Stage Biologics Program Ai Ching Lim, Director, Research, Amgen Advances In Protein Engineering, Design & Selection Stream Keynote Address: Protein Engineering At Shire Biotherapeutics: Manufacturing, Chemistry, Analytics And Control Stream Keynote Address: Innovating Bioactive Biomaterials As A Path Forward, Beyond Standard Biologics Angela Norton, Senior Director and Head, Protein & Antibody Engineering, Shire Pharmaceuticals Vincent Ling, Senior Director, Takeda Pharmaceuticals Solution Provider Presentation Solution Provider Presentation Morning Coffee & Refreshments, Poster Presentation Sessions, One to One Meetings x GPCR Structural Biology For Drug Discovery: Through The Protein Science Lens Developability Profiling And Engineering Studies To Support Developability Sujata Sharma, Director, Protein Science, Merck & Co., Inc Improving Circulating Half-Life Of Biopharmaceuticals By Polymer Conjugation Polymer based half-life extension technologies Chemical and enzymatic protein conjugation strategies PK/PD improvements of protein polymer conjugates Carsten Behrens, Principal Scientist, Novo Nordisk A/S Emma Harding, Director, Head of Molecular Design and Engineering, GlaxoSmithKline Process Development And cgmp Manufacture Of Recombinant Botulinum Neurotoxins Botulinum neurotoxin is effective in the treatment of several movement disorders. Native BoNT/A is comprised of a family of highly related neurotoxins produced by Clostridium botulinum bacteria and BoNT/A (subtype A1) is notable as the strain used to produce the commercial products abobotulinumtoxina (Dysport), onabotulinumtoxina (Botox), and incobotulinumtoxina (Xeomin). An increased understanding of the structure-function relationship of BoNT provides an opportunity to engineer recombinant (r) BoNTs with unique pharmacologic properties and therapeutic applications. This presentation will describe the construction, expression, purification, and characterization of rbont serotype A1 (rbont/a1) Targeted Secretion Inhibitors (TSI) are a novel class of recombinant biotherapeutic, developed by retargeting Botulinum neurotoxins for the treatment of diseases with secretion disorders. We describe the process development and cgmp manufacture of a TSI, SXN101959, a multi-domain, multi-functional recombinant protein expressed within Escherichia coli. SXN has been designed to possess a pituitary-specific site of action and to selectively inhibit growth hormone secretion from the pituitary During the manufacture of SXN101959, it is expressed as a single polypeptide chain and genetically engineered to contain a specific protease recognition sequence, which upon proteolytic cleavage produces the active di-chain product, held together via a disulphide bond. The SXN manufacturing process has been successfully scaled up to a 200 L bioreactor scale. SXN Drug Substance (DS) and liquid-formulated Drug Product (DP) were released in accordance with cgmp to supply GLP toxicology and clinical studies. An initial shelf life of one year was established for both DS and DP Andy Hooker, Director of Pharmaceutical Sciences, Ipsen Bioinnovation Ltd

5 Day One 16 th April 2018 Advances In Protein Engineering, Design & Selection Solution Provider Presentation Biotherapeutics: Manufacturing, Chemistry, Analytics And Control Solution Provider Presentation Lunch, Poster Presentation Sessions Inhibiting Interaction Of IL17A And Its Receptor Sepideh Afshar, Principal Research Scientist, Department of Protein Engineering, Eli Lilly & Company IMCgp100: A Novel TCR Based Immunotherapy Against Malignant Melanoma ImmTACTM molecules are bi-specific reagents that target tumors via a soluble monocloncal TCR with exceptionally high sensitivity and specificity and redirect host polyclonal T cells via an anti-cd3 antibody fragment. First in human studies with the lead ImmTAC, IMCgp100, show a favourable safety profile and promising signs of efficacy in both cutaneous and uveal melanoma. Development of IMCgp100 continues in uveal and cutaneous melanoma and in combination with checkpoint inhibitors. Annelise Vuidepot, Vice President, Head of Oncology Pipeline and Research, Immunocore Solution Provider Presentation A Novel Serum Stability Method To Guide Engineering And Selection Of Bi-Specifics Bi-specific domain orientation and variable region selection for optimal physical stability Novel in vitro screening method that predicts favorable drug-like properties Correlations between serum stability, in vivo PK, and biophysical properties W. Blaine Stine, Associate Director, Discovery Biologics, AbbVie Low Material Consuming, Highly Precise And Predictive Biophysical Methods For Biologics Developability Assessment Kinetics for thermal stability Activation energy barrier Long-terms stability prediction by computational biophysical approaches Alexey Rak, Head, BioStructure & Biophysics, Sanofi Solution Provider Presentation Afternoon Coffee & Refreshments, Poster Presentation Sessions, One to One Meetings x Advanced Computational Tools For Protein Engineering Yanay Ofran, Chief Executive Officer & Founder, Biolojic Design and Professor of Biophysics and Computational Biology, Bar-Ilan University Developability Assessment Of Therapeutic Proteins A Toolbox For Tackling Increasing Complexity The power of an integrated approach for candidate selection, combining information from expression and purification, physicochemical properties, solubility, stability, in vivo fitness etc. From platform approaches for standard molecules to project specific workpackage design for new formats Application of high throughput technologies enabling broad and efficient screenings for developability assessment Thorsten Lorenz, Group Head Developability Assessment 1, Novartis

6 Day One 16 th April 2018 Advances In Protein Engineering, Design & Selection Engineering Cytokines With Superior Pharmacokinetic Properties: The Ligand-Receptor Fusion Approach Using structural biology to inform fusion design Addressing the challenges of expression, oligomerization and glycosylation Jon Sayers, Professor of Functional Genomics, University of Sheffield Improving Protein Half-Life Extension, Potency & Selectivity Tina Møller Tagmose, Principal Scientist, Novo Nordisk A/S Biotherapeutics: Manufacturing, Chemistry, Analytics And Control Rapid Development Of HPLC-UV Based Multiple Quality Attributes Method Zhi Chen, Senior Scientist, Molecular and Analytical Development, Global Manufacturing & Supply, Bristol-Myers Squibb Application Of Solution NMR Spectroscopy For Characterizing (And Optimizing) Formulations Of mabs And Biopharmaceuticals Assessing how excipients affect self-association of monoclonal antibodies (mabs) and other protein-based biopharmaceuticals requires informative and direct measurements which work for highly concentrated solutions in situ. We show that solution NMR provides a number of useful measurable parameters very sensitive to transient protein association and protein-excipient interactions in different formulations; hence it can be used as a valuable assessment tool for choosing the best formulation which minimises self-association, aggregation and liquid-liquid phase separation, as well as for assessing long-term stability, interactions with excipients, etc. Alexander Golovanov, Senior Lecturer and Principal Investigator, Manchester Institute of Biotechnology and School of Chemistry, University of Manchester Biotherapeutics: Manufacturing, Chemistry, Analytics And Control Effect Of Project Acceleration And Breakthrough Designation On mab Development Front-loading versus fast to IND Manufacturing continuum Streamlining CMC package Minimizing upfront costs Berthold Boedeker, Chief Scientist and Project Coordination, Bayer AG Analytical Tool Box For Characterization Of Site Specific Isomerization In Monoclonal Antibodies Isomerization Focused peptide mapping Monoclonal antibodies Kaimeng Zhou, Analytical Team Lead, Bristol-Myers Squibb Supporting Robust Manufacturing With In-Depth Characterisation Of Biopharmaceutical Charge Variants Formation of charge variants (both acidic and basic species) is inevitable during biopharmaceutical manufacture The levels of these charge variants must be controlled, and their nature fully understood, for robust manufacturing of biotherapeutic products We show how charge variants and their formation mechanism were thoroughly characterised for the enzyme product Erwinaze, and how this supported robust manufacture from a quality and regulatory standpoint David Gervais, Head of Product Development, Porton Biopharma Drug-Like-Properties Of Fully Human Antibodies Derived From Human Ig Transgenic Mice Jane Seagal, Principal Research Scientist, AbbVie

7 Day One 16 th April Think Tank Round Table Discussions Table 1 Antibody Engineering & Evaluation Of Novel Therapeutic Candidates Moderator: W. Blaine Stine, Associate Director, Discovery Biologics, AbbVie Table 2 Immuno-Oncology Moderator: Roy Baynes, Chief Medical Officer, Senior Vice President and Head of Global Clinical Development, MSD Monotherapies Combination therapies Patient selection Table 3 Antibody Engineering, Development & Design Moderator: Stefan Weigand, Global Head of Large Molecule Research, F.Hoffmann-La Roche Bi- and multi-specifics: what's next? Format follows function: biology should be driver of engineering, but where are the boundaries (complexity, CMC development, immunogenicity,...) Full IgG - antibody fractions - fusion proteins: what are current trends in industry From binder to functional molecule: what are challenges to address increasingly complex biology Table 4 Cloning, Expression, Purification & Analytics Moderator: To Be Confirmed Table 5 Protein & Antibody Biotherapeutics Moderator: To Be Confirmed Networking Drinks & End of Day One

8 Day Two 17 th April th Annual Proteins & Antibodies Congress Keynote Address: PD-1 Antibody: A Broad Spectrum Anti-Cancer Agent Both As Monotherapy And In Combination Monotherapy activity across cancer types Progress in combination approaches Precision medicine to optimize treatment decisions Histology agnostic indications Roy Baynes, Chief Medical Officer, Senior Vice President and Head of Global Clinical Development, MSD Antibody Development, Engineering & Design Cloning, Expression, Purification & Analytics Protein & Antibody Biotherapeutics Stream Keynote Address: Integrated High Throughput Protein Purification And Analytics Stream Keynote Address: ph Dependent Target Binding Antibodies With Altered Affinity To FcRN: An Alternate Tool To Conventional Neutralizing Antibodies Antibodies with ph dependent binding to target antigens and neonatal Fc receptor provide an alternative tool to conventional neutralizing antibodies Antibodies with a range of ph dependent target binding properties can be identified by conventional antibody generation process Proposed mechanism results in highly efficient clearance of soluble targets from circulation thus significantly reducing physiological concentrations of the target Sanjaya Singh, Vice President and Head, Biotherapeutics, Johnson & Johnson Solution Provider Presentation Kenneth Walker, Director of Research, Biologics, Amgen Solution Provider Presentation Stream Keynote Address: Therapeutic Antibody Development At Teva, A Case Study Technology platforms Lead antibody identification Mechanism of action studies Steffen Nock, Senior Vice President (Global Biologics Head), Teva Pharmaceuticals Solution Provider Presentation Morning Coffee & Refreshments, Poster Presentation Sessions, One to One Meetings x Developing Bispecific Antibodies For Immuno- Oncology Recent Advancements In Protein Expression MAXCYTE Antibody Biotherapeutics Immuno-Oncology Case Study Syd Johnson, Vice President, Antibody Engineering, Macrogenics Solution Provider Presentation Darko Skegro, Senior Team Leader, Novartis Solution Provider Presentation Zhulun Wang, Executive Director, Research, Amgen Solution Provider Presentation

9 Day Two 17 th April 2018 Antibody Development, Engineering & Design Cloning, Expression, Purification & Analytics Protein & Antibody Biotherapeutics The Salipro System For Stabilization Of Membrane Proteins Salipro nanoparticles allow for the reconstitution of membrane proteins in a lipid environment: GPCRs, Transporters, Channels, Receptors Nanoparticles adjust to size of membrane proteins, incorporation of monomers as well as large homo/heterooligomeric complexes Technology allows to work with membrane proteins in detergent-free buffer systems Salipro-Membrane-Proteins enable high-resolution cryoem, structural studies, drug screenings and generation of antibodies Engineering ph Dependent Binding Antibodies To Overcome Target Mediated Clearance In Vivo Celgene Biotherapeutics Case Study From The Area Of Immuno-Oncology Claire Dobson, Associate Director, Antibody Discovery and Protein Expression, MedImmune Lunch, Poster Presentation Sessions A Tale Of Two mabs: Impacts Of The Same Unpaired Cysteines On Two Different Recombinant Monoclonal Antibodies Yung-Hsiang Kao, Associate Director and Principal Scientist, Genentech TCR-Like Antibodies: Generation And Characterization We have generated highly selective antibodies to the WT1 RMPNAPYL peptide:mhc I complex (pmhc) These antibodies bind pmhc with a TCR-like geometry We can use these antibodies to gain access to targets normally not accessible by traditional therapeutic antibodies Michael Chin, Senior Principal Scientist and Associate Research Fellow, Pfizer Jens Frauenfeld, Chief Executive Officer, Salipro Biotech AB Innovative Platform Technologies For Antibody Detection Patrick Garidel, Associate Director, Protein Chemistry, Boehringer Ingelheim Fusion Protein Engineering And Expression Screening Ramu Sadhukhan, Principal Research Scientist, AbbVie Hari Hariharan, Senior Director, Biotherapeutics, Celgene Roche's Approach To Discover, Design, Develop And Deliver Next Generation Protein Therapeutics Biologics have become a key component in the treatment of various life-threatening diseases. The majority of these drugs are classical monoclonal antibodies. In order to discover, design, develop and deliver differentiated, monoclonal antibodies, Roche's strategy is based on the identification of the best possible binder and engineering technologies that allow for tailored solutions for the biological problem at hand. This talk will briefly introduce Roche s approach to next gen protein therapeutics tailored for the biological problem at hand. Concept will be explained by presenting several examples including bi-specifics for multi-pathway-inhibition, fusion proteins, and molecules designed to cross the blood-brain-barrier. Stefan Weigand, Global Head of Large Molecule Research, F.Hoffmann-La Roche Biologics Research: More Better Faster Biologics are key modality for sustainable success of pharma companies. The benefit of biologics is in their high specificity, efficacy and tolerability. Sanofi is committed to becoming a leader in biologics and the company is continuously building and improving on its biologics capabilities and capacity. This presentation will discuss different elements that are relevant for building an efficient biologics research organization that delivers with high quality and on time, and satisfies internal research demands for biologics. Katarina Radošević, Global Head Biologics Research, Sanofi R&D

10 Efficient Expression Of Multi-Chain Bispecific Antibodies In CHO Cells Bispecific antibodies Expression in CHO cell 11 th Annual Proteins & Antibodies Congress Day Two 17 th April 2018 Antibody Development, Engineering & Design Cloning, Expression, Purification & Analytics Protein & Antibody Biotherapeutics Genetic Engineering Of CHO Cells Site Specific Manipulation And Targeted Integration Specific Immune Response To PLBL2, A Host Cell Impurity In Clinical Material A product related impurity was identified in the material used in clinical study. To assess the potential ability of patients to develop an immune response to the impurity and impact on immunogenicity of the therapeutic two bridging ELISA were developed and validated. Samples from treated subjects were evaluated in both assays. This presentation will discuss the results of the immunogenicity assessment to the impurity and observed immunogenicity rate of the antibody therapeutic. Ren Liu, Team Leader and Associate Principal Scientist, Merck & Co., Inc. Christian Bernloehr, Project Leader, Molecular Biology Department, Boehringer Ingelheim Afternoon Coffee & Refreshments, Poster Presentation Sessions Engineering Of Highly Selective Anti-Aβ42 Antibody With Picomolar Affinity For The Treatment Of Alzheimer s Disease Latest Developments On MicroRNAs For Next- Generation Cell Engineering MicroRNAs constitute an important class of non-coding RNAs. MEDI1814 is a novel, highly potent and selective inhibitor Individual mirnas control entire bioprocess relevant cellular of the most neurotoxic forms of the amyloid beta peptide, pathways and thus receive growing attention in biotechnology. Aβ x-42, whilst sparing the non-toxic forms of Aβ 40 Our comprehensive mirna research in a variety of production The antibody engineering, in vitro characterisation and preclinical in vivo evaluation will be presented generation of a mirna target catalog providing an avenue for cell lines with different genetic backgrounds led to the next-generation CHO cell engineering. Christopher Lloyds, Senior Scientist, Senior Scientist, Protein Engineering, MedImmune Kerstin Otte, Professor, University of Applied Sciences Biberach Antibody Development, Engineering & Design Developability Assessments For Selection Of Final Candidates An overview of the developability assessment of pre-clinical candidates at Janssen will be given at the presentation The characterization of the NIST IgG1 material will be described in the presentation Two Specific case studies with a focus in the assessment of bispecific candidates will be included in the presentation Dorina Saro, Senior Research Scientist, Johnson & Johnson Sally Fischer, Principal Scientist and Group Leader, Genentech Novel Monoclonal Antibody Therapies For Serious Infections Antibodies, including monoclonal antibodies have a rich history of therapeutic success, but only recently have mabs been applied to serious infectious diseases mabs have unique features that make them particularly suited to the modern challenges of infections, including the rapid, global emergence of antimicrobial resistance Targeted mabs can be used to pre-empt disease, and current mab discovery and development approaches overcome the traditional concerns over the use of biologics as anti-infectives Specific examples of challenges and opportunities will be reviewed, along with select data to demonstrate the great potential of mabs to treat and prevent serious infections David Mantus, Chief Development Officer, Arsanis Protein & Antibody Biotherapeutics Chlorotoxin In Peptide Drug Conjugates: MoA Studies Identify Its True Tumor Target Chlorotoxin is a tumor targeting peptide that naturally occurs in scorpion venom; as a radio-labeled peptide it proved efficacious in human glioma clinical trials Peptide Drug Conjugate (PDC) with chlorotoxin to target tumors and cryptophycin as warhead has a promising pharmacological profile preclinically Several proposed targets previously described for chlorotoxin do not align with the observed PDC activity Comprehensive analysis of MoA of chlorotoxin reveals its true target which is distinct and separate from its toxic properties in venom Sharon McGonigle, Senior Principal Scientist, Eisai

11 Day Two 17 th April 2018 Protein & Antibody Biotherapeutics Development Of An Integrated Novel Antibody Discovery Platform Using Single B Cell Technologies Discovery of therapeutic monoclonal antibodies by using proprietary B cell technology platform. The integrated novel antibody discovery platform enables high throughput and efficient discovery and generation of fully human therapeutic antibodies from antigen specific single B cells. Integration of single cell next-generation sequencing in the antibody discovery process facilitates discovery of broader and diverse antibody repertoire. Pallavi Tawde, Single B Cell Cloning Platform Leader, Bristol-Myers Squibb Targeting Immune Checkpoints An F-Star Case Study Michelle Morrow, Director, Preclinical Translational Pharmacology, F-Star Biotechnology End of Conference

12 11th Annual Proteins & Antibodies Congress Conference: April 2018 London UK HOW TO REGISTER: FAX your booking form to +44(0) PHONE on +44(0) Delegate Details Please complete fully and clearly. Please photocopy for additional delegates Title: Forename: Surname: Job Title: Company/Organisation: Address: Postcode: Country: Direct Telephone Direct Fax: Mobile: Switchboard: Registration Fees I would like to attend: (Please tick as appropriate) Industry Delegates (Biopharma, Pharma or Biotech Companies) Congress 799 plus VAT 1 day pass 499 plus VAT Day 1 Day 2 Academic Delegates Congress 499 plus VAT 1 day pass 299 plus VAT Day 1 Day 2 Vendor Delegates (CROs, Consultants, Technology and Service Providers) Congress Only 1750 plus VAT 1 day pass 999 plus VAT Day 1 Day 2 Signature: Poster Presentation 250 plus VAT Date: Terms & Conditions of Booking Agreed Terms between the Organiser (Oxford Global Marketing Ltd) and the Delegate: Delegate Booking Fee The Delegate Booking Fee includes: lunches and refreshments throughout the Congress event, conference presentations, workshop and panel sessions, scheduled one-to-one meetings and networking/social events, conference and speaker notes. Delegates may attend, free of charge, all sessions arranged by the Organiser. An admin surcharge of 50 + VAT will be applied to payments settled following the receipt of an invoice. This charge will not be applied to payments settled online. Vendor Delegates will not be eligible for one to one meetings unless they purchase a sponsorship meetings package. These can only be purchased directly from Oxford Global Marketing Ltd and not via the online booking facility. Poster Presentations Those who have booked a poster presentation at the event must provide the poster title, abstract (200 words or less), principal author, organisation, mailing address, , telephone, fax and additional authors, within a month of registration. All poster spaces will be for A0 (841mm x 1189mm) portrait size. Cancellation and Curtailment Delegates and vendor delegates are subject to the following charges and refunds upon withdrawal or cancellation. More than 6 months prior 35% cancellation fee / 65% refund Between 6 and 3 months prior 75% cancellation fee/ 25% refund Less than 3 months prior to the event Full cancellation fee / No refund Data Protection The data controller is the Organiser. The Organiser may disclose such personal information to Registered Event Sellers (Solution Providers) and other Delegates but solely for the purposes of the Event. The Delegate consents to the use of his/ her personal and company information on the terms set out herein. Miscellaneous This Agreement may not be transferred or assigned by either the Delegate or the Delegate s Company. The Organiser will determine the scope and content of Congress conference events, seminars, workshops and activities throughout the Event. The Organiser reserves the right to cancel the Event without liability to Delegate s Company or individual Delegate. If for any reason the Organiser has to cancel or postpone this Event, the Organiser reserves the right to transfer this Booking to another Congress within the same sector to be held within twelve months. Should another Congress in the same sector not be available within this period, the Booking Fee will be refunded. I agree to the above Terms and Conditions PROMOTIONAL LITERATURE DISTRIBUTION Distribution of your company s promotional literature to all conference attendees 999 plus VAT Documentation I cannot attend but would like to purchase access to the following: Access to the online conference presentations 499 plus VAT Conference presentations - paper copy 499 plus VAT VAT is charged at 20% on the attendance fees for all delegates. VAT is also charged on online and paper copy documentation and promotional literature distribution for all UK customers and for those EU customers not supplying a registration number for their own country here. How to Pay (choose one of the following payment options) Number of delegates: Industry del(s) Academic dels(s) Vendor dels(s) Special Offer: 3 for 2 Offer is only valid on the congress and for those registering at Industry or Academic rates CREDIT CARD: Visa MasterCard Maestro Amex Credit Card Number: Valid from: / Expiry Date: / Security code: Cardholders name: Signature: Date: PLEASE INVOICE ME: Invoice Address (if different from above) *Please note there is a 50 plus VAT handling charge for payment via invoice *All card payments will be subject to a 3% bank charge or 4% AMEX charge If you have any further queries please call the marketing team on +44(0) or marketing@oxfordglobal.co.uk